Wuhan Union Hospital is conducting a clinical trial is to learn if (N01; a combination therapy of steroids, IVIG, and romiplostim) works, and is safe, to treat severe primary immune thrombocytopenia in adults between the ages of 18-75 years. The main goal is to determine the effectiveness of the drug in ITP patients with severe primary immune thrombocytopenia during the initial treatment period for one month. Participants will be included if they have a platelet count less than 10×109/L with active bleeding. Participants will be unable to join the study if they are unable to receive steroids, romiplostim, or IVIG, and to who have had a prior splenectomy. Participants will also be unable to join the study if they have received romiplostim for treatment in the past, or at least one first-line ITP treatment, or required emergency treatment.
China
Actively Recruiting